title: [Celsior's kidney preservation in renal transplantation. Our experience].
abstract: BACKGROUND
  The goal of this research is to make a comparative analysis of acute tubular necrosis (NTA) incidence in function of preservation solution used: Wisconsin vs Celsior.
  
  
  METHODS
  From January 1994 to December 2002, 229 kidney transplantation procedures were executed; 190 of them were perfused with Wisconsin (82.9%) and 39 with Celsior (17.1%). After checking the statistical homogeneity of both groups, we analysis comparatively the incidence of NTA and the evolution of serum creatinine in function of preservation solution utilized.
  
  
  RESULTS
  There was not statistical significant difference in NTA incidence between Celsior (23%) and Wisconsin group (36%). We assessed that each group were comparable with regard to NTA incidence of subgroups with cold ischemia times longer 12 hours. Creatinine serum in Celsior group tended to be lower than Wisconsin group at 1, 3, 6 and 12 months posttransplantation (statistically significant difference, p<0.05)
  
  
  CONCLUSIONS
  Kidney preservation in Celsior solution provides similar results to the ones obtained in Wisconsin solution in relation with NTA incidence and kidney function with the added advantage of a lower cost.
authors.affiliation: Servicio de Urología, Hospital Ramón y Cajal, Madrid.
authors.forename: P
authors.initials: P
authors.lastname: Pérez Sanz
authors.forename: F J
authors.initials: FJ
authors.lastname: Burgos Revilla
authors.forename: R
authors.initials: R
authors.lastname: Marcén Letosa
authors.forename: J
authors.initials: J
authors.lastname: Pascual Santos
authors.forename: J L
authors.initials: JL
authors.lastname: Merino Rivas
authors.forename: J
authors.initials: J
authors.lastname: Ortuño Mirete
mesh_terms: D000241:Adenosine / Q000009:adverse effects; D000328:Adult; D000493:Allopurinol / Q000009:adverse effects; D004187:Disaccharides / Q000009:adverse effects; D004573:Electrolytes / Q000009:adverse effects; D005260:Female; D005971:Glutamates / Q000009:adverse effects; D005978:Glutathione / Q000009:adverse effects; D006639:Histidine / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D007328:Insulin / Q000009:adverse effects; D019194:Ischemic Preconditioning; D016030:Kidney Transplantation / Q000502:physiology; D007683:Kidney Tubular Necrosis, Acute / Q000139:chemically induced / Q000453:epidemiology; D008297:Male; D008353:Mannitol / Q000009:adverse effects; D008875:Middle Aged; D019188:Organ Preservation Solutions / Q000009:adverse effects; D011887:Raffinose / Q000009:adverse effects; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: C088453:Celsior; D004187:Disaccharides; D004573:Electrolytes; D005971:Glutamates; D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D008353:Mannitol; D006639:Histidine; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose